On 9 October 2026 the FDA recorded a supplement to an abbreviated new drug application for generic olanzapine (ANDA 210968). Supplements to generic applications usually concern manufacturing, labelling alignment with the reference product or packaging. The record does not describe a new indication, dose or safety finding.
Nothing changes for prescribing. Olanzapine remains widely available as a generic in India, and the usual metabolic monitoring applies.
- No change to olanzapine indications, dosing or monitoring follows from this record
- Continue baseline and periodic weight, glucose and lipid checks on olanzapine
- Check the labelled source for any change if a specific generic product is involved
Why it matters
It is a reminder that most regulatory entries for established antipsychotics are housekeeping, not safety signals.
Don't overread it
A generic licence supplement is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free